News

2008-10-01 NewConnect conquered by Euroimplant

Euroimplant, a Polish biotech company from Raszyn, is consistently increasing value of their stocks on NewConnect. During the last month price of stocks raised 50% and 30% in last few sessions and, as a consequence, was noted with the highest price since entering NewConnect. Recent events on NewConnect indicate increasing significance of biotech and pharma companies: Read-Gene, Pharmena and Euroimplant.

“Euroimplant executive board has observed increasing company value last months with satisfaction” – said Dariusz Sladowski, Euroimplant CEO. “Stock exchange quotations indicate that our efforts were appreciated by investors. In context of global markets crisis, it is a great achievement. The company is consistently implementing established strategy by working on patent protection of its products and technology, on development and preparation of perspective scientific and industrial base”.

Additionally Euroimplant is establishing new international connections which can soon result in official collaborations supported by the great potential of tissue engineering in Europe. “The executive board will do their best to maintain dynamic company growth and satisfy our investors” – said Sladowski.

Euroimplant is the biggest Polish biotech company. It was established in 2006 and is focused on designing and implementation of innovative biomedical solutions. Strategic target of the company is to develop and implement innovative tissue engineering solutions to the European market, and as a consequence to become an important player on the international market.

K. Kowalski, M. Mackowski